Search

Your search keyword '"I. O. Belogortsev"' showing total 3 results
Start Over Author "I. O. Belogortsev"
3 results on '"I. O. Belogortsev"'

1. Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia

Author

A. A. Rumyantsev, A. E. Protasova, M. Yu. Sheremet, A. Yu. Goryainova, M. V. Volkonskiy, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, O. V. Romanchuk, V. N. Orlova, N. G. Graft, M. R. Ibragimova, Yu. I. Merzlikina, L. V. Stepura, L. B. Tatulova, A. A. Abasova, A. A. Akopyan, E. V. Arsenyeva, Yu. V. Vasilyeva, A. V. Belonogov, L. V. Krivolapova, A. A. Bobryshev, D. Yu. Vovk, I. A. Luev, N. R. Abidova, R. S. Zhikhorev, T. A. Zhelezkova, T. T. Grigoryan, T. A. Makarkina, V. A. Ekimov, A. V. Zhizhina, E. V. Karabina, O. A. Kuchevskaya, V. M. Filippova, T. A. Linchenko, A. A. Lisaeva, A. N. Fedorova, K. S. Maystrenko, E. V. Markizova, E. V. Kogay, E. P. Krasnorutskaya, M. E. Popova, Yu. Yu. Pchelin, R. A. Ryanzhina, D. B. Sidorov, E. B. Shakhnovich, S. M. Alekseev, M. V. Zinkevich, I. O. Belogortsev, V. A. Chubenko, V. M. Moiseenko, N. Kh. Abduloeva, A. A. Lebedinets, L. V. Strakh, L. K. Semenov, M. B. Bolieva, and F. Z. Aydaeva

Subjects
targeted therapy, pembrolizumab, lenvatinib, endometrial cancer, routine clinical practice, Gynecology and obstetrics, RG1-991
Abstract

Aim. To assess the efficacy and safety of lenvatinib and pembrolizumab for the treatment of mismatch repair-proficient endometrial cancer (EC) in routine clinical practice in Russia.Materials and methods. This multicenter, retrospective, cohort study included patients with recurrent and metastatic EC from 37 cancer centers in Russia treated between May 2020 and April 2023. Patients with histologically verified EC without microsatellite instability who received ≥1 course of pembrolizumab/lenvatinib therapy were included in the study. The primary endpoint was progression-free survival; the clinical characteristics of the patients were additionally analyzed, the objective response rate and the toxicity profile of therapy were assessed.Results. The study included 100 patients. Median age was 65 (30–83) years. The most common histologic tumor subtype was endometrioid adenocarcinoma (68 %); serous adenocarcinoma was diagnosed in 22 % of cases, other types of tumor – 10 % of cases. All patients had pMMR/microsatellite-stable tumors. The median progression-free survival was 7.75 months (95 % confidence interval 0.7–33.8), and a partial response to therapy was observed in 24 % of patients. Almost half of the patients (44 %) required dose reduction due to adverse events. The most common adverse events included fatigue (n = 26; 26 %), hypertension (n = 20; 20 %), and hypothyroidism (n = 14; 14 %).Conclusion. This study confirms the clinical efficacy of lenvatinib and pembrolizumab in patients with recurrent and metastatic EC without mismatch repair system deficiency (pMMR-tumors) in routine clinical practice.

Published
2024
Full Text
View/download PDF

2. COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY

Author

M. E. Topuzov, A. E. Pryalukhin, I. O. Belogortsev, V. A. Zubarev, and S. S. Vodop’Yan

Subjects
prostate biopsy, prostate cancer, methods of anesthesia for prostate biopsy, Surgery, RD1-811
Abstract

Prostate biopsy guided by transrectal ultrasonography (TRUS) is largely used in prostate cancer diagnostics. This procedure is usually quite painful and fear of pain could scare patients from this important research. The aim of the study was to compare methods of anesthesia for prostate biopsy. The patients were divided into 4 groups (40 patients in each group). TRUS-guided periprostatic anesthesia with 1% solution of lidocaine (10 ml) was carried out in the first group. An intrarectal introduction of 5 g EMLA cream (lidocaine 2,5% and prilocaine 2,5%) was applied in the second group. The intrarectal introduction of 10% lidocaine spray (3 doses) was used in the third group. Placebo as ultrasonic gel was utilized for the fourth group. The authors used the 100- score linear visual analog scale (LVS 1-100) and 5-score numeric visual scale (NVS-4). Minimal scores of pain were obtained in patients using TRUS-guided periprostatic anesthesia with 1% solution of lidocaine (10 ml). This type of anesthesia didn’t lead to increase of the number of complications.

Published
2015
Full Text
View/download PDF

3. [COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY]

Author

M E, Topuzov, A E, Pryalukhin, I O, Belogortsev, V A, Zubarev, and S S, Vodop'yan

Subjects
Dosage Forms, Image-Guided Biopsy, Male, Visual Analog Scale, Prostate, Lidocaine, Pain, Prostatic Neoplasms, Middle Aged, Administration, Rectal, Outcome Assessment, Health Care, Humans, Analgesia, Anesthetics, Local, Ultrasonography, Interventional, Aged
Abstract

Prostate biopsy guided by transrectal ultrasonography (TRUS) is largely used in prostate cancer diagnostics. This procedure is usually quite painful and fear of pain could scare patients from this important research. The aim of the study was to compare methods of anesthesia for prostate biopsy. The patients were divided into 4 groups (40 patients in each group). TRUS-guided periprostatic anesthesia with 1% solution of lidocaine (10 ml) was carried out in the first group. An intrarectal introduction of 5 g EMLA cream (lidocaine 2,5% and prilocaine 2,5%) was applied in the second group. The intrarectal introduction of 10% lidocaine spray (3 doses) was used in the third group. Placebo as ultrasonic gel was utilized for the fourth group. The authors used the 100-score linear visual analog scale (LVS 1-100) and 5-score numeric visual scale (NVS-4). Minimal scores of pain were obtained in patients using TRUS-guided periprostatic anesthesia with 1% solution of lidocaine (10 ml). This type of anesthesia didn't lead to increase of the number of complications.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results